Background
HIV-1 envelope glycoprotein (Env) is expressed on the surface of infected cells, making it an attractive target for the clearance of these cells through antibody-mediated immune activities, such as antibody-dependent cellular cytotoxicity (ADCC). It was previously demonstrated that treatment with temsavir (TMR), a small molecule, can enhance the binding of the broadly neutralizing antibody (bnAb) N6, leading to improved clearance of HIV-1 infected cells. TMR is the active form of fostemsavir (FTR), a drug approved for use in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection. TMR binds to and stabilizes Env in a ‘closed’ conformation, which facilitates better recognition of Env by N6 and potentially other bnAbs.
Methods
To investigate whether TMR can modulate Env binding on infected cells by bnAbs other than N6, we conducted flow cytometry studies using HIV-1 infected primary CD4+ T cells. CD4+ T cells that were isolated from healthy PBMCs were infected with HIV-1 and treated with TMR for 24h prior to measurement of antibody binding in flow cytometry.
Results
We found that TMR treatment enhances binding of most bnAbs, including antibodies targeting CD4bs, V1V2, V3 glycans and gp120/41 interface with the exception of 10E8, to HIV-1 infected cells, leading to increased clearance of infected cells through ADCC. The enhanced binding of bnAb by TMR treatment is most prominently observed on infected cells that maintain CD4 expression, the cells that are otherwise difficult to target by bnAbs alone. When tested with a panel of clinical isolate viruses, TMR was found to enhance bnAb binding at concentrations similar to its antiviral potency. This suggests that the mechanism of action (MOA) is on-target and that this synergistic effect could potentially be achieved in clinical settings with approved doses of FTR. In kinetics experiments, we found that effective enhancement of antibody binding was observed with a treatment duration of 6h and longer, but a treatment duration of 30min was insufficient to produce this benefit.
Conclusions
Our results demonstrate that TMR treatment enhances antibody binding to the infected cells that maintain CD4 expression with a majority of bnAbs, at concentrations similar to the antiviral potency of TMR. These suggest that combining bnAbs with TMR can broaden the range of HIV-1 infected cells susceptible to antibody-mediated clearance, potentially increasing the likelihood of reservoir reduction in clinical settings.
Table or Figure
![]()